Coronary Artery Disease

FDA panel again rejects wider use of J&J's Xarelto

A panel of Food and Drug Administration experts again opposed expanding use of Johnson & Johnson's blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease.

Jan 16, 2014
popularity not rated yet | comments 0

Latest Spotlight News

More genetic clues found in a severe food allergy

Scientists have identified four new genes associated with the severe food allergy eosinophilic esophagitis (EoE). Because the genes appear to have roles in other allergic diseases and in inflammation, the ...

Dominant people can be surprisingly social

In contrast to the lay stereotype, dominant people prove to be avid social learners, just like dominant individuals in the animal kingdom. Neuroscientists from Radboud University show this with a complex ...

Dopamine leaves its mark in brain scans

Researchers use functional magnetic resonance imaging (fMRI) to identify which areas of the brain are active during specific tasks. The method reveals areas of the brain, in which energy use and hence oxygen ...